Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Prothena Public Limited's Business Segments
Prothena Public Limited's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
3
Largest Segment
License
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - FY
- License0%
- Collaboration0%
- Collaboration Program, Global, Prx01999%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| License | $ 50 | - |
| Collaboration | $ 2 | - |
| Collaboration Program, Global, Prx019 | $ 1 | 99% |
Revenue by Product & Service Category - FY
- License98%
- Collaboration2%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License | $ 50 | 98% |
| Collaboration | $ 1 | 2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- License0%
- Collaboration0%
- Collaboration Program, Global, Prx01999%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| License | $ 50 | - |
| Collaboration | $ 2 | - |
| Collaboration Program, Global, Prx019 | $ 1 | 99% |
Description of Prothena Public Limited
Prothena Corporation Public Limited Company is a clinical-stage biotechnology company based in Dublin, Ireland. It was established in 2012 and is primarily focused on the discovery, development, and commercialization of novel protein immunotherapies for the treatment of neurodegenerative diseases.
One of the key aspects of Prothena's work is its expertise in the field of misfolded and amyloidogenic proteins, which are believed to play a crucial role in the development and progression of neurodegenerative diseases such as amyloidosis, Parkinson's disease, Alzheimer's disease, and other related disorders. The company's research is centered around developing therapies that can target and neutralize these harmful proteins in order to prevent or slow down disease progression.
Prothena has a robust drug discovery and development platform that combines proprietary computational algorithms, structural biology techniques, and protein engineering expertise. This enables the company to identify and generate high-quality therapeutic antibodies, which are then optimized for efficacy, safety, and pharmacokinetic properties.
The company's lead product candidate, PRX002, also known as RG7935, is being developed in collaboration with Roche. PRX002 is an investigational monoclonal antibody that targets alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. The development program for PRX002 is currently in Phase 2 clinical trials, with the aim of evaluating its safety, tolerability, and efficacy in patients with Parkinson's disease.
In addition to PRX002, Prothena has a pipeline of other potential protein immunotherapies targeting various proteins, including tau, Aβ, and TTR, which are associated with neurodegenerative diseases. These candidates are at various stages of preclinical and clinical development.
Furthermore, Prothena has established collaborations with other pharmaceutical companies, research institutions, and academic partners to explore additional therapeutic targets and develop novel therapies for neurodegenerative diseases. The company also actively pursues partnerships and licensing agreements to advance its pipeline and leverage its expertise in protein immunotherapies.
In terms of its corporate structure, Prothena is a public limited company, meaning that it has raised capital from public investors through an initial public offering (IPO) and trades its shares on a stock exchange. Its stock is listed on the NASDAQ Global Market under the ticker symbol PRTA.
Overall, Prothena Corporation Public Limited Company is a pioneering biotechnology firm with a strong focus on developing innovative protein immunotherapies for the treatment of neurodegenerative diseases. Its robust drug discovery platform, strategic partnerships, and diverse pipeline make it a prominent player in the field of neurodegenerative disease research and development.
One of the key aspects of Prothena's work is its expertise in the field of misfolded and amyloidogenic proteins, which are believed to play a crucial role in the development and progression of neurodegenerative diseases such as amyloidosis, Parkinson's disease, Alzheimer's disease, and other related disorders. The company's research is centered around developing therapies that can target and neutralize these harmful proteins in order to prevent or slow down disease progression.
Prothena has a robust drug discovery and development platform that combines proprietary computational algorithms, structural biology techniques, and protein engineering expertise. This enables the company to identify and generate high-quality therapeutic antibodies, which are then optimized for efficacy, safety, and pharmacokinetic properties.
The company's lead product candidate, PRX002, also known as RG7935, is being developed in collaboration with Roche. PRX002 is an investigational monoclonal antibody that targets alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. The development program for PRX002 is currently in Phase 2 clinical trials, with the aim of evaluating its safety, tolerability, and efficacy in patients with Parkinson's disease.
In addition to PRX002, Prothena has a pipeline of other potential protein immunotherapies targeting various proteins, including tau, Aβ, and TTR, which are associated with neurodegenerative diseases. These candidates are at various stages of preclinical and clinical development.
Furthermore, Prothena has established collaborations with other pharmaceutical companies, research institutions, and academic partners to explore additional therapeutic targets and develop novel therapies for neurodegenerative diseases. The company also actively pursues partnerships and licensing agreements to advance its pipeline and leverage its expertise in protein immunotherapies.
In terms of its corporate structure, Prothena is a public limited company, meaning that it has raised capital from public investors through an initial public offering (IPO) and trades its shares on a stock exchange. Its stock is listed on the NASDAQ Global Market under the ticker symbol PRTA.
Overall, Prothena Corporation Public Limited Company is a pioneering biotechnology firm with a strong focus on developing innovative protein immunotherapies for the treatment of neurodegenerative diseases. Its robust drug discovery platform, strategic partnerships, and diverse pipeline make it a prominent player in the field of neurodegenerative disease research and development.
Prothena Corporation Public Limited Company is a biotechnology firm focused on developing innovative therapies for neurodegenerative diseases and other serious conditions. Their efforts are largely centered on monoclonal antibodies and other protein-based therapeutics that target various pathways involved in disease processes.
Segments
Prothena operates primarily in the following segments within the biotechnology and pharmaceutical industry:
1. Neurodegenerative Disease Therapeutics: This is Prothena’s core area of focus. The company aims to address diseases characterized by the progressive degeneration of the structure and function of the nervous system, such as Alzheimers disease, Parkinsons disease, and other tau-related disorders.
2. Immunotherapies: The company also explores immunotherapy treatments—using the body’s immune system to fight diseases. This segment includes products designed to harness or enhance the immune response against specific targets.
3. Monoclonal Antibodies: Prothena specializes in monoclonal antibody therapies, which are engineered to target specific proteins involved in disease progression. These antibodies can be designed to either inhibit pathological processes or promote beneficial responses.
4. Partnerships and Collaborations: Prothena actively engages in collaborations with other biotechnology and pharmaceutical companies to enhance research and development of their therapeutic candidates. These partnerships can range from co-development agreements to licensing deals.
Products
While Prothena has a number of clinical candidates in its pipeline, the following products are noteworthy:
1. PRX002 / ABBV-181: This is a monoclonal antibody developed for the treatment of Parkinsons disease by targeting alpha-synuclein, a key protein implicated in the pathology of the disease. Prothena has partnered with AbbVie to further the development of this candidate.
2. PRX005: This is another monoclonal antibody targeting tau, a protein associated with neurodegeneration, particularly in tauopathies like Alzheimers disease. The goal with PRX005 is to provide a potential disease-modifying treatment.
3. PRX004: Similar in its focus on tau pathology, this therapeutic candidate is being investigated for its potential to treat conditions where tau aggregation plays a critical role.
4. PRX011: A candidate addressing specific protein aggregates that may contribute to neurodegenerative diseases. The details of this product may revolve around the underlying mechanisms of protein misfolding and aggregation.
Services
Alongside its product offerings, Prothena also provides certain services related to biotechnology development, including:
1. Research and Development Services: Engaging in extensive R&D to explore new therapeutic targets, optimize drug candidates, and conduct preclinical and clinical studies.
2. Partnership Development: Prothena plays a role in forming strategic partnerships to enhance the development of their candidates, offering co-development opportunities to other entities.
3. Regulatory Support: Providing guidance and support in navigating the various regulatory requirements associated with clinical trials and product commercialization.
4. Scientific Consultation: Offering insights and expertise in biotherapeutic development and the underlying science of neurodegenerative disorders.
Through this extensive combination of segments, products, and services, Prothena Corporation positions itself as a key player in addressing significant health challenges associated with neurodegenerative diseases. Their focus on innovative monoclonal antibodies and collaborations aims to bring transformative therapies to market and improve patient outcomes.
Segments
Prothena operates primarily in the following segments within the biotechnology and pharmaceutical industry:
1. Neurodegenerative Disease Therapeutics: This is Prothena’s core area of focus. The company aims to address diseases characterized by the progressive degeneration of the structure and function of the nervous system, such as Alzheimers disease, Parkinsons disease, and other tau-related disorders.
2. Immunotherapies: The company also explores immunotherapy treatments—using the body’s immune system to fight diseases. This segment includes products designed to harness or enhance the immune response against specific targets.
3. Monoclonal Antibodies: Prothena specializes in monoclonal antibody therapies, which are engineered to target specific proteins involved in disease progression. These antibodies can be designed to either inhibit pathological processes or promote beneficial responses.
4. Partnerships and Collaborations: Prothena actively engages in collaborations with other biotechnology and pharmaceutical companies to enhance research and development of their therapeutic candidates. These partnerships can range from co-development agreements to licensing deals.
Products
While Prothena has a number of clinical candidates in its pipeline, the following products are noteworthy:
1. PRX002 / ABBV-181: This is a monoclonal antibody developed for the treatment of Parkinsons disease by targeting alpha-synuclein, a key protein implicated in the pathology of the disease. Prothena has partnered with AbbVie to further the development of this candidate.
2. PRX005: This is another monoclonal antibody targeting tau, a protein associated with neurodegeneration, particularly in tauopathies like Alzheimers disease. The goal with PRX005 is to provide a potential disease-modifying treatment.
3. PRX004: Similar in its focus on tau pathology, this therapeutic candidate is being investigated for its potential to treat conditions where tau aggregation plays a critical role.
4. PRX011: A candidate addressing specific protein aggregates that may contribute to neurodegenerative diseases. The details of this product may revolve around the underlying mechanisms of protein misfolding and aggregation.
Services
Alongside its product offerings, Prothena also provides certain services related to biotechnology development, including:
1. Research and Development Services: Engaging in extensive R&D to explore new therapeutic targets, optimize drug candidates, and conduct preclinical and clinical studies.
2. Partnership Development: Prothena plays a role in forming strategic partnerships to enhance the development of their candidates, offering co-development opportunities to other entities.
3. Regulatory Support: Providing guidance and support in navigating the various regulatory requirements associated with clinical trials and product commercialization.
4. Scientific Consultation: Offering insights and expertise in biotherapeutic development and the underlying science of neurodegenerative disorders.
Through this extensive combination of segments, products, and services, Prothena Corporation positions itself as a key player in addressing significant health challenges associated with neurodegenerative diseases. Their focus on innovative monoclonal antibodies and collaborations aims to bring transformative therapies to market and improve patient outcomes.